Revolution Medicines GAAP EPS of -$0.78 beats by $0.01, revenue of $7.58M misses by $1M

May 09, 2022 4:54 PM ETRevolution Medicines, Inc. (RVMD)By: Anuron Mitra, SA News Editor
  • Revolution Medicines press release (NASDAQ:RVMD): Q1 GAAP EPS of -$0.78 beats by $0.01.
  • Revenue of $7.58M (-25.2% Y/Y) misses by $1M.
  • Reiterates full year 2022 GAAP net loss to be between $260 million and $290 million.
  • Cash, cash equivalents and marketable securities were $518.8 million as of March 31, 2022, compared to $577.1 million as of December 31, 2021.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.